Skip to content

Technology in Motion (TIM): Unobtrusive assessment of motor (dys)function

Technology in Motion (TIM): Unobtrusive assessment of motor (dys)function - TIM

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43825
Enrollment
250
Registered
2015-11-17
Start date
2016-02-08
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular accident (CVA stroke)

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: General: 18 years or older, male/female, have command of the Dutch language. Additional for stroke: survivor of a cerebrovascular accident (stroke) Additional for PD: Diagnosed with PD according to the UK PD Brain Bank criteria Additional for patients with tremor: tremor of the hand and/or arm, having a scheduled visit for tremor assessment at the Clinical Neurophysiology outpatient clinic at LUMC. Additional for healthy controls: normal function of both arms, normal gait and balance function, normal cognitive function (MoCA score > 26), normal or corrected to normal vision

Exclusion criteria

Exclusion criteria: General: * additional neurological diseases and/or orthopedic problems interfering with hand/arm function or balance/gait function * unable to comply with the protocol, i.e. insufficient general fitness or cognitive/communicative inability to understand instructions and participate in the measurement * inability to walk with help of one person (for the *gait and balance* experiment only);Additional for stroke: *

Design outcomes

Primary

MeasureTime frame
Kinematic parameters obtained for reaching and grasping (e.g., maximum active range of motion, accuracy, velocity and smoothness of reach and grasp movements), for gait and balance (e.g., step length, step time, gait asymmetry, performance on an obstacle avoidance task), and for tremor (frequency, amplitude) as a function of task- and environmental conditions.

Secondary

MeasureTime frame
Clinical test scores For stroke patients in general: Montreal Cognitive Assessment, Letter Cancellation Test, Beck Depression Index and Nottingham Extended Activities of Daily Living; Additional for stroke patients participating in the *reaching and grasping* experiment: Fugl-Meyer - Upper Extremity, Action Research Arm Test, Ashworth score of the elbow and wrist, Erasmus modification of the Nottingham Sensory Assessment - Upper Extremity and Michigan Hand Outcome Questionnaire; Additional for stroke patients participating in the "gait and balance" experiment: Timed Up-and-Go, 10 m walk test, Functional Reach test, Tinetti Balance Assessment, short version of the Berg Balance Scale, Falls Efficacy Scale * International, Ashworth score of the knee and ankle, and the Modified Survey of Activities and Fear of Falling in the Elderly Scale For PD patients in general: Movement Disorder Society version of the Unified Parkinson Disease Rating Scale [MDS-UPDRS], the Scales for Outcomes in Parkinson*s Disease - Cognition [SCOPA-COG] and Psychiatric Complications [SCOPA-PC], Beck Depression Index and Questionnaire for Impulsive-Compulsive Disorders in Parkinson*s Disease * Rating Scale [QUIP-RS]; Additional for PD patients participating in the *reaching and grasping* experiment: Michigan Hand Outcome Questionnaire; Additional for PD patients participating in the "gait and balance" experiment: Timed Up-and-Go, 10 m walk test, Functional Reach test, Tinetti Balance Assessment, short version of the Berg Balance Scale, Falls Efficacy Scale * International, the New Freezing of Gait questionnaire, the Modified Survey of Activities and Fear of Falling in the Elderly Scale, and the SEverity of Non-dopaminergic Symptoms in Parkinson*s Disease scale. For patients with tremor: Bain and Findley Clinical tremor rating scale, Bain and Findley tremor ADL scale Other: age, sex, education level, work, dominant side, (most) affected side, disease duration, curre

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)